STOCK TITAN

Jasper Therapeutics (JSPR) DEF 14A Filings

JSPR NASDAQ

Here are the DEF 14A proxy statements from Jasper Therapeutics, Inc. (JSPR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow JSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JSPR filings page.

Rhea-AI Summary

Jasper Therapeutics, Inc. asks stockholders at a virtual special meeting on November 13, 2026 to approve common-stock issuance upon conversion of preferred stock issued for its completed Kira acquisition and $132 million PIPE financing, ratify Patrick Crutcher’s board appointment, and authorize adjournment if needed. The merger closed July 16, 2026, and the PIPE financing closed July 20; the merger itself is not up for approval. Conversion could result in a maximum 604,302,051 common shares—320,289,040 merger-related and 284,013,011 PIPE-related—subject to beneficial-ownership limits. Taken together, the Merger Preferred, PIPE Preferred and Kira Options would represent approximately 95% of issued and outstanding Common Stock as of September 28, 2026 on an as-converted basis.

Conversion is also subject to sufficient authorized shares and conditional Nasdaq approval, and Jasper says issuance would dilute existing holders. The company disclosed it no longer meets Nasdaq’s $1.00 minimum bid-price and $2,500,000 stockholders’ equity requirements; the bid-price compliance period ends November 30, 2026. Stockholders authorized a 1-for-15 to 1-for-35 reverse split, but the board has not effected it or selected a ratio. The board recommends “FOR” all four proposals.

Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) is calling a virtual special stockholder meeting on September 30, 2026 to vote on three capital-structure proposals. The first would authorize the board, any time through December 31, 2026, to implement a reverse stock split of common stock at a ratio between 1‑for‑15 and 1‑for‑35, without changing the 490,000,000 authorized common shares. This is primarily intended to help regain compliance with Nasdaq’s $1.00 minimum bid requirement after a notice received on June 3, 2026; the stock last closed at $0.6864 on September 3, 2026. The second proposal would increase authorized common shares from 490,000,000 to 675,000,000, mainly to ensure enough shares to convert 9,555,390 preferred shares issued in connection with the Kira Pharmaceuticals acquisition and a concurrent financing. As of August 10, 2026, common shares outstanding were 33,274,561. The third proposal would allow adjournment of the meeting to solicit more proxies if needed. The board recommends voting FOR all three proposals and notes that each is considered a “routine” matter for broker voting.

Rhea-AI Summary

Jasper Therapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on July 31, 2026 at 10:00 a.m. Pacific Time. Stockholders of record as of June 5, 2026, when 28,009,802 common shares were outstanding, may vote online or by proxy.

Investors are asked to elect two Class II directors (Judith Shizuru and Tom Wiggans), ratify PricewaterhouseCoopers LLP as the independent auditor for 2026, and approve on an advisory basis executive compensation. The proxy explains voting mechanics, quorum requirements, broker non-votes, and outlines board structure, committee responsibilities, and non-employee director fees and option grants.